Pre-clinical (animal) studies have found that Molnupiravir has remarkably reduced SARS-CoV-2 load and was found to have completely suppress...

Backorders and complaints over low supply started moderating in the second week of May, the drugmaker said, after it began ramping up produ...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...